Who is sponsoring NCT06864767?

NCT06864767 is sponsored by Zeynep HOŞBAY.

What drugs are being tested in NCT06864767?

Interventions in NCT06864767: Neuro-sensory Motor Developmental Assessment, Functional Oral Intake Scale, Behavioral Pediatrics Feeding Assessment Scale, Pediatric Quality of Life Inventory.

What condition does NCT06864767 study?

NCT06864767 studies Spinal Muscular Atrophy Type I.

Is NCT06864767 still recruiting?

NCT06864767 is currently completed. Last updated 7 March 2025.

Last reviewed 2025-03-07 · How we verify

NCT06864767

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of Motor and Oral Motor Function on Quality of Life in Children With SMA

Completed Last updated 7 March 2025

What this trial tests

trial testing Neuro-sensory Motor Developmental Assessment in Spinal Muscular Atrophy Type I in 23 participants. Completed in 30 August 2024.

Timeline

30 May 2024

Primary endpoint
15 June 2024

30 August 2024

Quick facts

Lead sponsor	Zeynep HOŞBAY
Status	Completed
Study type	OBSERVATIONAL
Enrollment	23
Start date	30 May 2024
Primary completion	15 June 2024
Estimated completion	30 August 2024
Sites	1 location across Turkey (Türkiye)

Drugs / interventions tested

Neuro-sensory Motor Developmental Assessment
Functional Oral Intake Scale
Behavioral Pediatrics Feeding Assessment Scale
Pediatric Quality of Life Inventory

Conditions studied

Spinal Muscular Atrophy Type I — all drugs for Spinal Muscular Atrophy Type I →

Sponsor

Zeynep HOŞBAY

Who can join

Adults 2 to 4, any sex, with Spinal Muscular Atrophy Type I. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to investigate the impact of motor and oral motor functions on the quality of life in children aged 2-4 years diagnosed with Spinal Muscular Atrophy (SMA) Type I. In the study, the Neuro-Sensory-Motor Developmental Assessment (NSMDA) was used to evaluate motor functions, the Functional Oral Intake Scale (FOIS) to assess oral motor function, the Behavioral Pediatric Feeding Assessment Scale (BPFAS) to evaluate children's attitudes towards feeding, and the Pediatric Quality of Life Inventory (PedsQL) Neuromuscular Module to assess quality of life.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Spinal Muscular Atrophy Type I

Currently open trials in the same condition.

NCT04042025 — Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06864767 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zeynep HOŞBAY
Last refreshed: 7 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06864767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing